Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | CD69 | Q07108 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | AMY2A | P04746 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31702077 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL29441447 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL30654147 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL30652110 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL29632877 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL31700517 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL31700297 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL31700504 | 1.00 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL31700524 | 0.99 | LGALS3 (0.58) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL31700947 | 0.99 | LGALS3 (0.58) | LGALS3LGALS8LGALS4CD69ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380485-A1 | SINGLE DOMAIN ANTIBODIES SPECIFICALLY BINDING GLOBO - SERIES GLYCANS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380485-A1 | SINGLE DOMAIN ANTIBODIES SPECIFICALLY BINDING GLOBO - SERIES GLYCANS | STT3B, STT3A, GOLGA3 | LGALS3 19/4885LGALS8 70/4885LGALS4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.